{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05396105",
            "orgStudyIdInfo": {
                "id": "PHA022121-C303"
            },
            "organization": {
                "fullName": "Pharvaris Netherlands B.V.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema",
            "officialTitle": "A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-Inhibitor Deficiency (Type I or Type II)",
            "acronym": "RAPIDe-2",
            "therapeuticArea": [
                "Other"
            ],
            "study": "extension-study-of-oral-pha-for-acute-treatment-of-angioedema-attacks-in-patients-with-hereditary-angioedema"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-12-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-28",
            "studyFirstSubmitQcDate": "2022-05-24",
            "studyFirstPostDateStruct": {
                "date": "2022-05-31",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-05-10",
            "lastUpdatePostDateStruct": {
                "date": "2023-05-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pharvaris Netherlands B.V.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks, in patients with HAE due to C1-esterase inhibitor (C1-INH) deficiency (type I/II). The study will enroll patients from Study PHA022121-C201 (NCT04618211) who elect to participate in this extension study and meet the eligibility requirements.",
            "detailedDescription": "In Part A of the study, the double-blind treatment assignment from Study PHA022121-C201 will be maintained. The treatment in Part A will consist of 3 soft capsules per administered dose as in Study PHA022121-C201. In Part B of the study, the selected dose and formulation of deucrictibant will be administered.\n\nThe to-be-marketed deucrictibant formulation will be one single soft capsule at the strength proposed for marketing, based on the unblinding and evaluation of clinical data from Study PHA022121-C201. The duration of the treatment period (Part A plus Part B) is dependent upon the time of patient enrollment. The study is planned to continue until the availability of commercial supply, or another means of continued treatment can be provided."
        },
        "conditionsModule": {
            "conditions": [
                "Hereditary Angioedema",
                "Hereditary Angioedema Type I",
                "Hereditary Angioedema Type II",
                "Hereditary Angioedema Types I and II",
                "Hereditary Angioedema Attack",
                "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
                "Hereditary Angioedema - Type 1",
                "Hereditary Angioedema - Type 2",
                "C1 Esterase Inhibitor [C1-INH] Deficiency",
                "C1 Esterase Inhibitor Deficiency",
                "C1 Esterase Inhibitor, Deficiency of",
                "C1 Inhibitor Deficiency"
            ],
            "keywords": [
                "HAE",
                "HAE Type I",
                "HAE Type II",
                "Oral Treatment",
                "Bradykinin B2 Receptor Antagonists",
                "On-Demand",
                "PHA121",
                "PHVS416",
                "PHA-022121",
                "Deucrictibant"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2",
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 72,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part A: Low dose",
                    "type": "EXPERIMENTAL",
                    "description": "Single low dose of deucrictibant",
                    "interventionNames": [
                        "Drug: deucrictibant low dose"
                    ]
                },
                {
                    "label": "Part A: Medium dose",
                    "type": "EXPERIMENTAL",
                    "description": "Single medium dose of deucrictibant",
                    "interventionNames": [
                        "Drug: deucrictibant medium dose"
                    ]
                },
                {
                    "label": "Part A: High dose",
                    "type": "EXPERIMENTAL",
                    "description": "Single high dose of deucrictibant",
                    "interventionNames": [
                        "Drug: deucrictibant high dose"
                    ]
                },
                {
                    "label": "Part B: Selected dose",
                    "type": "EXPERIMENTAL",
                    "description": "Single dose of deucrictibant",
                    "interventionNames": [
                        "Drug: deucrictibant selected dose"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "deucrictibant low dose",
                    "description": "deucrictibant soft capsules for oral use",
                    "armGroupLabels": [
                        "Part A: Low dose"
                    ],
                    "otherNames": [
                        "PHVS416",
                        "PHA121",
                        "PHA-022121"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "deucrictibant medium dose",
                    "description": "deucrictibant soft capsules for oral use",
                    "armGroupLabels": [
                        "Part A: Medium dose"
                    ],
                    "otherNames": [
                        "PHVS416",
                        "PHA121",
                        "PHA-022121"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "deucrictibant high dose",
                    "description": "deucrictibant soft capsules for oral use",
                    "armGroupLabels": [
                        "Part A: High dose"
                    ],
                    "otherNames": [
                        "PHVS416",
                        "PHA121",
                        "PHA-022121"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "deucrictibant selected dose",
                    "description": "deucrictibant soft capsule for oral use",
                    "armGroupLabels": [
                        "Part B: Selected dose"
                    ],
                    "otherNames": [
                        "PHVS416",
                        "PHA121",
                        "PHA-022121"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Treatment-emergent Adverse Events (TEAEs), treatment-related TEAEs, treatment-emergent serious adverse events (TESAEs), and treatment-related TESAEs",
                    "timeFrame": "From enrollment through study completion, up to 40 months (dependent on time of enrollment)."
                },
                {
                    "measure": "Heart Rate",
                    "description": "Descriptive in nature, no formal statistical hypothesis testing will be performed.",
                    "timeFrame": "From enrollment through study completion, up to 40 months (dependent on time of enrollment)."
                },
                {
                    "measure": "Blood pressure",
                    "description": "Systolic and diastolic blood pressure will be measured. Descriptive in nature, no formal statistical hypothesis testing will be performed.",
                    "timeFrame": "From enrollment through study completion, up to 40 months (dependent on time of enrollment)."
                },
                {
                    "measure": "Body temperature",
                    "description": "Descriptive in nature, no formal statistical hypothesis testing will be performed.",
                    "timeFrame": "From enrollment through study completion, up to 40 months (dependent on time of enrollment)."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to onset of symptom relief (TOSR) assessed by the 3- or 5-symptom visual analog scale score (VAS-3 or VAS-5)",
                    "description": "VAS-3 (non-laryngeal attacks) and VAS-5 (laryngeal attacks) scores range between 0 and 100. Symptom relief is defined as a 50% or higher reduction of the VAS-3 or VAS-5 score from the pre-treatment value.",
                    "timeFrame": "Assessed from pre-treatment to 48 hours post-treatment"
                },
                {
                    "measure": "Time to almost complete or complete symptom relief (TACSR and TCSR) assessed by VAS-3 or VAS-5",
                    "description": "VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 or VAS-5 having a value \\< 10. Complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 or VAS-5 having a value of 0.",
                    "timeFrame": "Assessed from pre-treatment to 48 hours post-treatment"
                },
                {
                    "measure": "Time to symptom improvement based on patient global impression of severity (PGI-S)",
                    "description": "PGI-S evaluates the severity of attack symptoms with a 5-point response scale.",
                    "timeFrame": "Assessed from pre-treatment to 48 hours post-treatment"
                },
                {
                    "measure": "Time to symptom improvement based on patient global impression of change (PGI-C)",
                    "description": "PGI-C evaluates the change in the attack symptoms over time with a 7-point response scale.",
                    "timeFrame": "Assessed from pre-treatment to 48 hours post-treatment"
                },
                {
                    "measure": "Change of VAS-3 score and individual VAS score from pre-treatment to 4 h post-treatment for non-laryngeal attacks",
                    "description": "VAS-3 scores range between 0 and 100. A larger reduction means a better outcome.",
                    "timeFrame": "Pre-treatment and 4 hours post-treatment"
                },
                {
                    "measure": "Change in Mean symptom complex severity (MSCS) score",
                    "description": "MSCS scores range between 0 and 3. A higher score means a worse outcome.",
                    "timeFrame": "Assessed from pre-treatment to 48 hours post-treatment"
                },
                {
                    "measure": "Treatment outcome score (TOS)",
                    "description": "TOS scores range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment.",
                    "timeFrame": "Assessed from pre-treatment to 4 hours post-treatment"
                },
                {
                    "measure": "Proportion of PHA-022121-treated attacks requiring a second dose of PHA-022121",
                    "timeFrame": "From enrollment through study completion, up to 40 months (dependent on time of enrollment)."
                },
                {
                    "measure": "Treatment satisfaction questionnaire for medication (TSQM) scores",
                    "description": "TSQM scores range from 0 to 100. A higher score means a better outcome.",
                    "timeFrame": "48 hours post-treatment"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Signed and dated informed consent form\n2. Diagnosis of HAE type I or II\n3. must have received at least 1 dose of study drug (including the non-attack visit) in Study PHA022121-C201.\n\nKey Exclusion Criteria:\n\n1. Pregnancy or breast-feeding\n2. Clinically significant abnormal electrocardiogram\n3. Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study\n4. Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrolment\n5. History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse\n6. Discontinued from Study PHA022121-C201 after enrollment for any study drug-related safety reason.\n7. Use of concomitant medications that are potent CYP3A4 inhibitors (e.g., clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir, grapefruit) or potent CYP3A4 inducers (e.g., phenytoin, rifampicin, St. John's Wort).\n8. Participation in any other investigational drug study within defined period",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pharvaris Clinical Team",
                    "role": "CONTACT",
                    "phone": "+31 (71) 203-6410",
                    "email": "clinicaltrials@pharvaris.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Marcus Maurer, Prof MD",
                    "affiliation": "Charite University, Berlin, Germany",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Study site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35209",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                },
                {
                    "facility": "Study site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Scottsdale",
                    "state": "Arizona",
                    "zip": "85258",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.50921,
                        "lon": -111.89903
                    }
                },
                {
                    "facility": "Study site",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Walnut Creek",
                    "state": "California",
                    "zip": "94598",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 37.90631,
                        "lon": -122.06496
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Sofia",
                    "country": "Bulgaria",
                    "geoPoint": {
                        "lat": 42.69751,
                        "lon": 23.32415
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Montr\u00e9al",
                    "state": "Quebec",
                    "country": "Canada",
                    "geoPoint": {
                        "lat": 45.50884,
                        "lon": -73.58781
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Brno",
                    "country": "Czechia",
                    "geoPoint": {
                        "lat": 49.19522,
                        "lon": 16.60796
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Grenoble",
                    "zip": "38043",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.16667,
                        "lon": 5.71667
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Paris",
                    "zip": "75010",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.85341,
                        "lon": 2.3488
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Berlin",
                    "zip": "10114",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 52.52437,
                        "lon": 13.41053
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Frankfurt am Main",
                    "zip": "60596",
                    "country": "Germany",
                    "geoPoint": {
                        "lat": 50.11552,
                        "lon": 8.68417
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Budapest",
                    "country": "Hungary",
                    "geoPoint": {
                        "lat": 47.49801,
                        "lon": 19.03991
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Ashkelon",
                    "country": "Israel",
                    "geoPoint": {
                        "lat": 31.66926,
                        "lon": 34.57149
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Krak\u00f3w",
                    "country": "Poland",
                    "geoPoint": {
                        "lat": 50.06143,
                        "lon": 19.93658
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08907",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Study site",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28007",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000000799",
                    "term": "Angioedema"
                },
                {
                    "id": "D000054179",
                    "term": "Angioedemas, Hereditary"
                },
                {
                    "id": "D000056829",
                    "term": "Hereditary Angioedema Types I and II"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000014581",
                    "term": "Urticaria"
                },
                {
                    "id": "D000017445",
                    "term": "Skin Diseases, Vascular"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000006969",
                    "term": "Hypersensitivity, Immediate"
                },
                {
                    "id": "D000006967",
                    "term": "Hypersensitivity"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000081208",
                    "term": "Hereditary Complement Deficiency Diseases"
                },
                {
                    "id": "D000081207",
                    "term": "Primary Immunodeficiency Diseases"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000007153",
                    "term": "Immunologic Deficiency Syndromes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4127",
                    "name": "Angioedema",
                    "asFound": "Angioedema",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27584",
                    "name": "Angioedemas, Hereditary",
                    "asFound": "C1 Esterase Inhibitor Deficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M28606",
                    "name": "Hereditary Angioedema Types I and II",
                    "asFound": "Hereditary Angioedema Type I",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17330",
                    "name": "Urticaria",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M19714",
                    "name": "Skin Diseases, Vascular",
                    "relevance": "LOW"
                },
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M10020",
                    "name": "Hypersensitivity, Immediate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6879",
                    "name": "Deficiency Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2286",
                    "name": "Hereditary Complement Deficiency Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2285",
                    "name": "Primary Immunodeficiency Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10199",
                    "name": "Immunologic Deficiency Syndromes",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T2734",
                    "name": "Hereditary Angioedema",
                    "asFound": "Hereditary Angioedema",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M26365",
                    "name": "Complement C1 Inhibitor Protein",
                    "relevance": "LOW"
                },
                {
                    "id": "M5197",
                    "name": "Bradykinin",
                    "relevance": "LOW"
                },
                {
                    "id": "M10725",
                    "name": "Kininogens",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                }
            ]
        }
    },
    "hasResults": false
}